Financial Performance - The company incurred net losses of $73.9 million and $35.1 million for the years ended December 31, 2024 and 2023, respectively, with an accumulated deficit of $229.9 million as of December 31, 2024[710]. - The company expects to continue incurring operating losses for the foreseeable future, with no products approved for sale and no revenue generated since inception[715]. - The accumulated deficit increased from $156.0 million in 2023 to $229.9 million in 2024[744]. Cash and Investments - The company had cash, cash equivalents, and marketable securities of $212.5 million as of December 31, 2024, sufficient to fund operations through 2027 based on current estimates[711]. - As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $212.5 million, up from $106.8 million in 2023[744]. - Net cash used in operating activities was $15.6 million in 2024, compared to $20.6 million in 2023, reflecting a net loss of $73.9 million[752][753]. - Net cash used in investing activities was $121.1 million in 2024, primarily due to purchases of marketable securities totaling $132.2 million[754]. - Net cash provided by financing activities was $130.7 million in 2024, mainly from the issuance of common stock in a private placement[757]. Research and Development - Research and development expenses totaled $65.995 million for the year ended December 31, 2024, a significant increase from $15.411 million in 2023[726]. - The company anticipates substantial increases in research and development expenses as it conducts ongoing clinical trials and studies[728]. - Budoprutug, the company's cornerstone product candidate, is in clinical development for primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, with FDA clearance for Phase 2 trials expected to begin in the second half of 2025[707]. - The company plans to announce preclinical data for the subcutaneous formulation of budoprutug in the first half of 2025 and initiate clinical development in the second half of 2025[707]. - CLYM116, a preclinical stage anti-APRIL monoclonal antibody, is being evaluated in IND-enabling studies, with preclinical data expected in the second half of 2025[708]. Operating Expenses - Total operating expenses increased by 103.6% from $40.3 million in 2023 to $82.0 million in 2024, primarily due to a $51.7 million expense related to acquired in-process research and development[736][737]. - General and administrative expenses decreased by 35.5% from $24.9 million in 2023 to $16.0 million in 2024, driven by a reduction in personnel-related expenses[741]. Internal Controls and Compliance - The company identified material weaknesses in internal control over financial reporting, with two remaining unremediated as of December 31, 2024[766]. - The company has a remediation plan for the identified material weaknesses in internal controls, disclosed in Item 9A of the Annual Report[766]. - The company is classified as an emerging growth company under the JOBS Act, allowing it to delay adopting new accounting standards until they apply to private companies[767]. - The company will remain an emerging growth company until it achieves total annual gross revenue of $1.24 billion or more, issues more than $1.0 billion of non-convertible debt, or meets other specified criteria[768]. Stock-Based Compensation - Stock-based compensation is measured based on estimated grant-date fair value, with the Black-Scholes option pricing model used for valuation[764]. - Changes in assumptions regarding stock-based compensation can materially affect the recognized expense in future periods[764]. Market Risk and Accounting Estimates - The company is not required to provide quantitative and qualitative disclosures about market risk as a smaller reporting company[769]. - The preparation of consolidated financial statements involves significant estimates and assumptions that may differ from actual results[762]. - Critical accounting estimates are those that require significant estimation uncertainty and could materially affect financial condition or results of operations[763]. - The consolidated financial statements may not be comparable to those of companies that comply with new accounting pronouncements as of public company effective dates[768].

Financial Position - Climb Bio has approximately $218 million in cash, cash equivalents, and marketable securities as of September 30, 2024, expected to fund operations through 2027[8]. Clinical Trials and Development - In the Phase 1b study of budoprutug for primary membranous nephropathy (pMN), 60% of patients achieved complete remission of proteinuria[5]. - Budoprutug demonstrated complete and sustained B-cell depletion in all patients, with undetectable levels of B-cells after just two doses as low as 100 mg[5]. - The company plans to initiate Phase 1b clinical trials in systemic lupus erythematosus (SLE) and immune thrombocytopenia (ITP) in the first half of 2025, subject to regulatory clearance[6][7]. - Budoprutug has been successfully formulated above 175 mg/ml for a potential subcutaneous dosing form, with non-clinical data expected in the first half of 2025[4]. - The strategic development of budoprutug targets three opportunity sets: IgG4-mediated diseases, IgG1-3 diseases affecting single organ systems, and complex systemic diseases[3]. - The company aims to advance the pMN clinical program to late-phase development expected in 2025[8]. - A single-arm, open-label study for chronic ITP will include a "treat-to-target" approach for personalized redosing based on individual patient needs[7]. - The Phase 1b trial in SLE will utilize serum biomarkers to accelerate proof-of-concept and optimize dosing[6]. Product Potential - Climb Bio emphasizes the potential of budoprutug as a differentiated anti-CD19 monoclonal antibody for B-cell mediated diseases[3].

Financial Performance - The company reported net losses of $8.9 million for Q3 2024, compared to $4.0 million for Q3 2023, and $65.5 million for the first nine months of 2024, compared to $31.5 million for the same period in 2023, indicating a significant increase in losses year-over-year [132]. - The company has an accumulated deficit of $221.5 million as of September 30, 2024, compared to $156.0 million as of December 31, 2023 [132]. - The net loss for the three months ended September 30, 2024, was $8.9 million, a 124.2% increase from a net loss of $4.0 million in the same period of 2023 [161]. - Total operating expenses for the nine months ended September 30, 2024, were $71.1 million, a 102.3% increase from $35.2 million in the same period of 2023 [166]. - Research and development expenses increased by 111.6% from $2.9 million for the three months ended September 30, 2023, to $6.1 million for the same period in 2024 [162]. - General and administrative expenses rose by 158.4% from $2.1 million for the three months ended September 30, 2023, to $5.5 million for the same period in 2024 [163]. - Acquired in-process research and development expense was $51.7 million for the nine months ended September 30, 2024, due to the acquisition completed on June 27, 2024 [167]. - General and administrative expenses decreased by 51.6% from $22.9 million for the nine months ended September 30, 2023 to $11.1 million for the nine months ended September 30, 2024 [169]. Cash and Funding - As of September 30, 2024, the company had cash, cash equivalents, and marketable securities totaling $217.9 million, up from $106.8 million as of December 31, 2023, providing sufficient funds to support operations through 2027 [133]. - The company anticipates that its cash, cash equivalents, and marketable securities will be sufficient to fund operations through 2027 [172]. - Net cash used in operating activities for the nine months ended September 30, 2024 was $10.0 million, consisting primarily of a net loss of $65.5 million [178]. - Net cash provided by financing activities for the nine months ended September 30, 2024 was $130.7 million, including $119.7 million from the issuance of common stock in a Private Placement [182]. - Net cash used in investing activities for the nine months ended September 30, 2024 was $67.7 million, primarily due to purchases of marketable securities [179]. - Future funding requirements will depend on various factors, including the timing and cost of research and development activities [173]. - The company may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development expenditures [175]. Clinical Development - In a Phase 1b clinical trial of budoprutug for primary membranous nephropathy (pMN), 60% of patients achieved complete remission of proteinuria, and complete B-cell depletion was observed in all patients [127][141]. - The FDA cleared the IND for budoprutug in systemic lupus erythematosus (SLE) in October 2024, with plans to initiate a Phase 1b clinical trial in the first half of 2025 [137][146]. - The company plans to initiate a Phase 2 clinical trial of budoprutug for immune thrombocytopenia (ITP) in the first half of 2025, pending IND clearance [129][146]. - Budoprutug was well-tolerated in clinical trials, with no drug-related serious adverse events reported, and no deaths among patients [143]. - The company plans to announce non-clinical data on the subcutaneous formulation of budoprutug in the first half of 2025 [149]. - The strategic focus includes developing budoprutug for IgG4-mediated diseases, IgG1-3 related diseases, and complex systemic diseases, with potential applications beyond current indications [140]. Acquisition Details - The company completed the acquisition of Tenet Medicines, Inc. on June 27, 2024, issuing 31,238,282 shares at $3.84 per share, raising approximately $120.0 million before expenses [131]. - The total cost of the asset acquisition of Tenet was $52.8 million, including $5.8 million in transaction costs and $5.0 million related to a loan settled upon closing [136].

Core Points - The company Eliem Therapeutics, Inc. has changed its name to Climb Bio, Inc. to reflect its new focus on developing treatments for immune-mediated diseases following the acquisition of Tenet Medicines, Inc. [1][2] - Climb Bio will begin trading on Nasdaq under the new ticker symbol "CLYM" effective October 3, 2024 [1] - The lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody with potential applications in various B-cell mediated diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy [2][4] Company Strategy - The name change and rebranding aim to symbolize the journey of patients with autoimmune diseases and the commitment to developing new treatments [2] - The company has refreshed its corporate website and adopted a new logo to align with its strategic direction [3] Product Development - Budoprutug, previously known as TNT119, is designed to deplete CD19-positive B cells, which may lead to a reduction in pathogenic autoantibodies [2] - In a Phase 1b clinical trial for membranous nephropathy, 60% of patients receiving four doses of budoprutug achieved complete remission of proteinuria [2]

Group 1 - Eliem Therapeutics, Inc. will participate in the Stifel 2024 Virtual Immunology and Inflammation Summit on September 17-18, 2024 [1] - The summit will feature 1x1 meetings format for discussions [1] - Eliem Therapeutics focuses on developing therapeutics for autoimmune-driven inflammatory diseases, including budoprutug, an anti-CD19 antibody [1] Group 2 - Budoprutug is designed for a broad range of autoimmune diseases, such as systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy [1]

Acquisition and Financial Position - Eliem completed the acquisition of Tenet Medicines in June 2024, focusing on therapeutics for autoimmune-driven inflammatory diseases[2]. - Eliem raised $120 million through a private placement of common stock concurrent with the acquisition, increasing cash and cash equivalents to $223.1 million as of June 30, 2024, compared to $106.8 million at the end of 2023[4]. - Acquired in-process research and development expense was $51.7 million for the three and six months ended June 30, 2024, due to the acquisition of Tenet Medicines[4]. - Total assets increased to $226.0 million as of June 30, 2024, from $110.5 million at the end of 2023, reflecting the impact of the acquisition[6]. - Eliem was added to the Russell 2000® Index and the Russell 3000® Index in June 2024, enhancing its visibility among institutional investors[2]. Research and Development Expenses - Research and Development (R&D) expenses decreased to $1.0 million for Q2 2024 from $3.7 million in Q2 2023, and total R&D expenses for the first half of 2024 were $2.1 million compared to $9.4 million in the same period of 2023[4]. General and Administrative Expenses - General and Administrative (G&A) expenses increased to $3.7 million for Q2 2024 from $3.0 million in Q2 2023, while total G&A expenses for the first half of 2024 were $5.6 million compared to $20.7 million in the same period of 2023[4]. Financial Performance - The net loss for Q2 2024 was $54.9 million, significantly higher than the $5.2 million loss in Q2 2023, with a total net loss of $56.6 million for the first half of 2024 compared to $27.5 million in the same period of 2023[4]. Corporate Strategy and Product Development - Eliem plans to host an Investor Day later in 2024 to provide updates on its corporate strategy and budoprutug development[3]. - Eliem's lead product candidate, budoprutug, is an anti-CD19-targeted monoclonal antibody aimed at treating various immune-mediated diseases[2].

Financial Performance - Eliem Therapeutics reported net losses of $54.9 million for Q2 2024, compared to $5.2 million in Q2 2023, and an accumulated deficit of $212.6 million as of June 30, 2024[99]. - Total operating expenses for the three months ended June 30, 2024, increased by 739.6% to $56.4 million from $6.7 million in the same period of 2023[1]. - Net loss for the three months ended June 30, 2024, was $54.9 million, a 951.5% increase from a net loss of $5.2 million in the same period of 2023[1]. - Net cash used in operating activities for the six months ended June 30, 2024, was $2.5 million, significantly lower than $23.1 million in the same period of 2023[6]. - Research and development expenses for the six months ended June 30, 2024, decreased by 77.3% to $2.1 million from $9.4 million in the same period of 2023[8]. - General and administrative expenses for the six months ended June 30, 2024, decreased by 73.1% to $5.6 million from $20.7 million in the same period of 2023[9]. Acquisition and Investment - The company completed the acquisition of Tenet Medicines on June 27, 2024, issuing 31,238,282 shares at $3.84 per share, raising approximately $120.0 million[98]. - The total cost of the Tenet acquisition was $52.8 million, including $5.8 million in transaction costs and $5.0 million related to a loan settled upon closing[103]. - Eliem recognized in-process research and development expense of $51.7 million for the three and six months ended June 30, 2024, due to the acquisition of Tenet[103]. - Net cash provided by financing activities for the six months ended June 30, 2024, was $128.4 million, primarily from the issuance of common stock[7]. Research and Development - In a Phase 1b clinical trial of budoprutug for membranous nephropathy, 60% of patients achieved complete remission of proteinuria[94]. - Eliem expects to finalize a high concentration formulation of budoprutug by the end of 2024 to support subcutaneous dosing[96]. - Research and development expenses are expected to increase substantially as the company conducts ongoing clinical trials and studies[107]. - Research and development expenses decreased by 71.6% from $3.7 million in Q2 2023 to $1.0 million in Q2 2024, primarily due to a pause in clinical trials[3]. Cash Position - Cash and cash equivalents were reported at $223.1 million as of June 30, 2024, sufficient to fund operations into 2027[100]. - Cash and cash equivalents as of June 30, 2024, were $223.1 million, sufficient to fund operations into 2027[5]. Corporate Strategy and Future Outlook - Eliem plans to provide a comprehensive update on its corporate and budoprutug development strategy at an Investor Day later this year[96]. - The company has not generated any revenue from product sales since inception and expects to continue incurring operating losses for the foreseeable future[102]. Accounting and Compliance - The company is classified as an emerging growth company under the JOBS Act, allowing it to delay adopting new accounting standards until they apply to private companies[137]. - The company will remain an emerging growth company until it achieves total annual gross revenue of $1.235 billion or more or meets other specified criteria[138]. - The company evaluates acquisitions to determine if they should be accounted for as business combinations or asset acquisitions based on the concentration of fair value in identifiable assets[134]. - The company’s financial statements are prepared in accordance with U.S. GAAP, requiring management to make estimates and assumptions that could materially affect reported amounts[133]. - There were no material changes to the company's critical accounting policies during the six months ended June 30, 2024[135]. - The company has obligations under an asset purchase agreement and certain license agreements, which include milestone and royalty payments contingent upon future events[132]. - The company accounts for future payments in asset acquisitions based on the achievement of regulatory, development, or sales milestones[134]. - The company’s consolidated financial statements may not be comparable to those of companies that comply with new accounting pronouncements as of public company effective dates[138]. - The company does not provide quantitative and qualitative disclosures about market risk as a smaller reporting company[139].

Core Insights - Eliem Therapeutics has completed the acquisition of Tenet Medicines and a concurrent $120 million private placement, positioning itself as a leading development stage immunology company focused on autoimmune diseases [2][3][4] - The company plans to develop its lead product candidate, budoprutug, an anti-CD19-targeted monoclonal antibody, for various immune-mediated diseases [2][3] - Eliem has approximately $220 million in cash and cash equivalents, expected to fund operations into 2027 and support key clinical milestones for budoprutug [3][4] Business Updates - The acquisition of Tenet Medicines allows Eliem to focus on therapeutics for autoimmune-driven inflammatory diseases, including systemic lupus erythematosus and immune thrombocytopenia [3][6] - Eliem appointed Aoife Brennan as President and CEO and Jan Hillson as Senior Clinical Advisor, enhancing its executive leadership team [3] - Eliem was added to the Russell 2000® Index and Russell 3000® Index, which are significant for investment managers and institutional investors [3] Financial Results - As of June 30, 2024, Eliem's cash and cash equivalents were $223.1 million, a significant increase from $106.8 million as of December 31, 2023 [4][7] - Acquired in-process research and development expenses were $51.7 million for the quarter, reflecting the acquisition of Tenet Medicines [4][8] - Eliem reported a net loss of $54.9 million for the three months ended June 30, 2024, compared to a net loss of $5.2 million for the same period in 2023 [5][8]

Core Insights - Eliem Therapeutics, Inc. is preparing to report additional results from its phase 1b study of TNT119 for membranous nephropathy, with expectations that these results could enhance shareholder value by the end of 2024 [2][8] - The company plans to initiate two phase 2 studies in the second half of 2024 targeting systemic lupus erythematosus and immune thrombocytopenia, which represent significant market opportunities [2][13] - Eliem recently completed a merger with Tenet Medicines, resulting in a new ownership structure where Eliem shareholders hold 85% and Tenet shareholders hold 15% of the combined entity [8][14] Clinical Development - The primary focus of Eliem's clinical program is the use of TNT119 for treating membranous nephropathy, an autoimmune disorder affecting kidney function [3][12] - Preliminary data from the phase 1b study indicated that 3 out of 5 patients achieved complete remission and all 5 patients achieved partial remission at 48 weeks, with no serious adverse events reported [12][14] - The global market for membranous nephropathy treatment is projected to reach $328.4 million by 2034, but the company aims to leverage TNT119 for broader applications in other autoimmune disorders [12][13] Financial Position - As of March 31, 2024, Eliem Therapeutics had approximately $105 million in cash, bolstered by a recent merger and a $120 million private placement, bringing total cash on hand to $220 million [14] - The company’s cash burn rate is approximately $3 million per quarter, providing a runway to fund operations into 2027 [14] Market Opportunities - The global market for systemic lupus erythematosus drugs is expected to reach $4.2 billion by 2031, while the immune thrombocytopenia market is projected to reach $3.3 billion by 2032 [13] - The potential for TNT119 to target a wider range of B-cells may provide a competitive edge over existing therapies, which typically target a narrower spectrum [12][13]

Core Insights - Eliem Therapeutics, Inc. has been included in the Russell 2000® Index and the broader Russell 3000® Index as part of the annual reconstitution, effective immediately [4] - The Russell indexes are widely utilized by investment managers and institutional investors, with approximately US$9.1 trillion in assets benchmarked against Russell's U.S. indexes as of May 2024 [5] - Inclusion in the Russell indexes is seen as a significant milestone for Eliem, enhancing its visibility and credibility in the market [10] Company Overview - Eliem Therapeutics focuses on developing therapeutics for autoimmune-driven inflammatory diseases, particularly advancing TNT119, an anti-CD19 antibody aimed at a range of autoimmune diseases including systemic lupus erythematosus and immune thrombocytopenia [11] - The company aims to harness the potential of TNT119, which is designed to have enhanced effector function [10] Industry Context - FTSE Russell, the provider of the Russell indexes, has over 30 years of experience and is a leading global index provider, offering benchmarks for investment performance and creating ETFs, structured products, and index-based derivatives [3][5] - FTSE Russell employs a transparent, rules-based methodology for index design and governance, adhering to high industry standards [7]